Why Compounded GLP-1 Prices Differ So Much Between Providers

Why is compounded semaglutide so cheap compared with Wegovy?

Wegovy and Zepbound are FDA-approved products made by Novo Nordisk and Eli Lilly and sold at prices those companies publish. Compounded semaglutide and tirzepatide are, in FDA's words, not FDA approved: the agency does not review them for safety, effectiveness, or quality before they are marketed. A compounding pharmacy prepares them from a bulk active ingredient for an individual prescription, without the approved product's supply chain, packaging, or pricing. The price gap is the gap between an approved brand product and an unapproved pharmacy preparation, and it says nothing about whether the two are equivalent. They are not, and FDA prohibits telehealth companies from claiming they are.

Within the compounded market the spread is wider still. The table lists the inputs that move a program's price, each of which is a choice the program makes rather than a property of the drug.

Why one provider charges more than another for the same drug name

Start with the pharmacy. FDA's questions-and-answers page explains that drugs compounded by 503B outsourcing facilities are subject to current good manufacturing practice requirements and FDA oversight, while 503A pharmacy compounding is not subject to CGMP and is overseen day to day by state boards. Those are different cost structures, and a program using one or the other will price differently. In 2026 a 503B source for semaglutide or tirzepatide also needs an explanation, since FDA has proposed keeping both drugs off the 503B bulks list.

Then the bundle. Sprout Health states that all prices displayed at checkout are comprehensive and include the fees for the mandatory doctor consultation; TelePep says the clinician consult fee is part of the price rather than a separate line item. CoreAge Rx keeps the consultation fee even when the provider declines. Ro bills a membership and states the cost of medication is not included in it. Two programs with the same medication charge can therefore differ by a consultation fee and a membership fee before a vial ships.

Then the dose and the term. Ageless publishes a range and says exact pricing depends on your prescribed dose, with the final amount shown after clinical review, so its headline number is the lowest dose. Its terms make multi-month discounts conditional on completing the selected plan term. A program advertising its cheapest prepaid, lowest-dose month against another program's monthly, mid-dose, all-inclusive price will look far cheaper without being cheaper for a given patient.

Does a cheaper compounded GLP-1 mean a weaker or fake product?

FDA has published what worries it about compounded GLP-1 products, and price is not on the list. Its September 2026 statement says some compounders use salt forms, including semaglutide sodium and semaglutide acetate, which are different active ingredients than are used in the approved drugs. It reports 990 adverse-event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide as of May 31, 2026, and multiple reports, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide. It tells patients to fill prescriptions at a state-licensed pharmacy and to be wary of labels naming pharmacies that cannot be verified.

FDA's general page on compounded-drug risks names contamination, too much active ingredient, insanitary conditions, and poor labeling. Every one of those can occur at any price. The questions that separate a sound product from a risky one are about the ingredient form, the pharmacy's license, the label, and the dosing instructions, and a program that answers them well at a low price is not suspect for being cheap. Equally, a high price buys nothing if the program will not name its pharmacy.

What the price does not tell you: who compounded it

FDA's June 2026 guidance to telehealth companies prohibits branding that falsely or misleadingly implies the telehealth company is the compounder, and its March 2026 warning letters to 30 companies cited advertising drugs branded with the telehealth firm's name or trademark without saying who made them. A price attached to a program-branded vial therefore hides the input that matters most. The compounder's identity determines whether the product is a 503A or 503B preparation, which state licenses it, and whether its label can be checked.

The FDA guidance also bars claiming a compounded drug is sourced from an FDA-approved or FDA-licensed pharmacy, a phrase some programs use to justify a premium. FDA approves neither compounded drugs nor pharmacies; 503B facilities register with FDA and 503A pharmacies are licensed by states. A program that quotes a price alongside a named, verifiable pharmacy is giving you the information; one that quotes a price alongside its own logo is not.

Why the advertised price may not be a monthly price at all

Several of the inputs above turn a price into a starting point. Dose-based pricing means the number applies to the lowest dose. Prepaid pricing means it applies only if you finish the term; Ageless reprices supplied months at the shorter-plan rate on early cancellation, and TelePep refunds unshipped months less an administrative fee. Introductory pricing means it applies to the first month. Membership pricing means it excludes the medication.

The catalog on this site normalizes those cases. Each program's row shows the price basis, the commitment, whether the price is introductory, and whether the medication is included, and the ranked comparison uses continuing, medication-included prices. A program's cheapest advertised figure and its comparable monthly price can be quite different numbers, and only the second one is worth comparing across programs.

How to compare compounded GLP-1 prices fairly

Six questions turn a list of headline prices into a comparison of the same thing.

• Which pharmacy compounds it, is it 503A or 503B, and can its license be verified with the state board or FDA's outsourcing-facility list?
• Is the active ingredient base semaglutide or tirzepatide, or a salt form FDA says is a different ingredient?
• What does the price include: medication, consultation, shipping, and follow-up?
• What dose does the price apply to, and what does the dose you are likely to reach cost?
• Is the price introductory or prepaid, and what is the continuing monthly price if you stop after one shipment?
• Does the marketing avoid the claims FDA prohibits, including any suggestion that the product is the same as Wegovy or Zepbound?

How Telehealth Ledger ranks compounded GLP-1 prices

The price module above ranks programs by the lowest current comparable medication-included price for the treatment, shows the number of comparable programs, and separates care-only, introductory, and unpriced structures so they are not mistaken for continuing prices. Each row carries its verification date and, where the program publishes one, a direct price source.

That is a comparison of what programs charge, not of what their pharmacies produce. It cannot rank quality, and no price list can. The pharmacy questions above are the buyer's to ask, and the program's to answer before payment.